The Scripps Research Institute - Lead Identification Lead ID Home Work With Us

Work With Us


Working With Us

For academic collaborators, a popular way to access our expertise and facilities is through NIH-sponsored mechanisms. Industrial and academic collaborators can also directly sponsor specific screening activities. Please contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call us at either (561) 228-2150 or (561) 228-2101 if you have any questions or need assistance with any of the opportunities listed below.

 

NIH-Funded Opportunities

The NIH has announced grant opportunities that fund the screening of Scripps’ Drug Discovery Library. This 640,000 compound library is unique to Scripps. Please click on the links below to be directed to information related to each grant:

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
arrow PAR-18-762

Posted Date: April 19, 2018
Expiration Date: May 8, 2021
Participating Organizations: NINDS
R01 Research Project: This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs. Activities for R61 phase include Assay development, validation and optimization for High-Throughput Screening (HTS). Activities for the R33 phase includes HTS, medicinal chemistry, assessment of initial pharmacokinetic and optimization of therapeutic agent(s) for in vivo testing.

Assay development and screening for discovery of chemical probes or therapeutic agents (R01)
arrow PAR-17-438

Posted Date: July 27, 2017
Expiration Date: Sep 8, 2020
Participating Organizations: NIMH, NIAID, NCI, NIDA, NIDCD
R01 Research Project: Through this funding opportunity announcement (FOA), NIH wishes to stimulate research in discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes; and to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets. Stages of discovery research covered by this FOA include: 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize hit set.

NIH Research Project Grant (Parent R01)
arrow PA-16-160

Posted Date: May 5, 2016
Expiration Date: May 8, 2019
Participating Organizations: All NIH institutes
R01 Research Project: The NIH Research Project Grant supports a discrete, specified, circumscribed project in scientific areas that represent the investigators' specific interests and competencies and that fall within the mission of the participating NIH Institutes and Centers (ICs). The R01 is the original, and historically the oldest, grant mechanism used by the NIH to support health-related research and development. Stages of discovery research that can be included: 1) assay development; 2) HTS/HCS primary screen implementation to identify initial screening hits (target-focused or phenotypic screens); 3) hit validation; 4.) medicinal chemistry SARs; and 5.) lead-optimization. Five years of support is adequate to support assay transfer, high throughput drug discovery, medicinal chemistry, DMPK pharmacology, target validation and MOA studies as well as preliminary in-vivo experimentation. SRIMSC can coordinate all services (1-5) as needed. Entry requires identification of a target and/or phenotypic response, preliminary assay data and a source of biologics (i.e. cell line, proteins, peptides) Projects are reviewed and transferred to SRIMSC to provided preliminary screening data for grant application.

Drug Discovery for Nervous System Disorders (R21)
arrow PAR-16-042

Posted Date: Nov 24, 2015
Expiration Date: Jan 8, 2019
Participating Organizations: NIMH, NIA, NIAAA, NIDA
R21 Exploratory/Developmental Research Grant Award: Research projects may include any activities required to identify, optimize, and validate potential therapeutic candidates and may propose studies focused on all stages of the early drug discovery pipeline, from screening to candidate selection. Examples of these activities may include, but are not limited to:

  • Development and validation of assays that permit the identification of therapeutic leads. These may include biochemical and cellular assays, modified model organisms, and electrophysiological or behavioral systems.
  • Preliminary identification of candidate therapeutics, using in vitro, ex vivo, or in vivo assays, which can be evaluated through further preclinical testing. This may include high, medium, or low-throughput assays, as well as counter-screening to assess the selectivity of hit and lead compounds.

Drug Discovery for Nervous System Disorders (R01)
arrow PAR-16-041

Posted Date: Nov 24, 2015
Expiration Date: Jan 8, 2019
Participating Organizations: NIMH, NIA, NIAAA, NIDA
R01 Research Project Grant: Research projects may include any activities required to identify, optimize, and validate potential therapeutic candidates and may propose studies focused on all stages of the early drug discovery pipeline, from screening to candidate selection. Examples of these activities may include, but are not limited to:

  • Development and validation of assays that permit the identification of therapeutic leads. These may include biochemical and cellular assays, modified model organisms, and electrophysiological or behavioral systems.
  • Preliminary identification of candidate therapeutics, using in vitro, ex vivo, or in vivo assays, which can be evaluated through further preclinical testing. This may include high, medium, or low-throughput assays, as well as counter-screening to assess the selectivity of hit and lead compounds.

Building on High Impact Basic Neurobiology Through Assay Development: Advancing Tools for Therapeutic Discovery
arrow PAR-15-066

Posted Date: December 10, 2014
Expiration Date: January 8, 2018
Participating Organizations: NIMH, NIAAA, NIDA
R01 Research Project: This funding opportunity announcement (FOA) is aimed at developing novel, robust assays to reveal changes in neuronal and/or glial function. The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function with the intent to probe mechanisms or perturbations in an unbiased and efficient manner. These novel assays would provide opportunities to measure neurobiological endpoints and build a pipeline to be used in the context of target identification and drug discovery. In general, assays should have the potential to enable an unbiased screen of hundreds to thousands of perturbations (e.g., small molecules, siRNAs, peptides, etc.).

Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21)
arrow PAR-17-335

Posted Date: July 24, 2017
Expiration Date: September 8, 2020
Participating Organizations: NIMH, NEI, NIDA, NIDCD
R21 Research Project: This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. This program creates an opportunity for integrated research in biology and chemistry on structure-activity relationships (SAR) of novel compounds through an iterative and parallel optimization process, to advance successful development of cell-based chemical probes. Applicants to this FOA should have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds.

Discovery of in vivo Chemical Probes for Novel Brain Targets (R01)
arrow PAR-17-336

Posted Date: July 24, 2017
Expiration Date: September 8, 2020
Participating Organizations: NIMH, NEI, NIDA, NIDCD
R01 Research Project: This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of cell-based chemical probes for novel brain targets. It is expected that applicants will have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. This program creates an opportunity for integrated research in biology and chemistry on structure-activity relationships (SAR) of novel compounds through an iterative and parallel optimization process, to advance successful development of cell-based chemical probes. Applicants to this FOA should have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds.

Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)
arrow PAR-15-070

Posted Date: December 11, 2014
Expiration Date: May 8, 2018
Participating Organizations: NINDS, NIDA
R21/R33 Research Project Grant: This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for NINDS Cooperative Research to Enable and Advance Translational Enterprises program (CREATE) for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational program.

Discovery of Small Molecule Immunomodulators for Cancer Therapy (R01)
arrow PAR-17-331

Posted Date: July 20, 2017
Expiration Date: September 8, 2020
Participating Organizations: NCI
R01 Research Project: The purpose of this funding opportunity announcement (FOA) is to promote the discovery of novel small molecules that may enhance the ability of the immune system to selectively recognize and attack cancer cells. This FOA encourages the following phases of discovery research: 1) assay development specifically designed for immuno-oncology targets with the intent to screen for novel small molecule compounds that show potential as either probes or drugs, or as pre-therapeutic leads; 2) screen implementation for immunomodulatory targets to identify initial screening hits (from high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches); 3) hit validation through secondary orthogonal and counter screening assays, and hit prioritization; and 4) hit-to-lead optimization.

Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01)
arrow PAR-17-189

Posted Date: March 3, 2017
Expiration Date: April 4, 2020
Participating Organizations: NICHD, NIDCD
R01 Research Project: The purpose of this funding opportunity announcement (FOA) is to encourage applications for translational and clinical research as well as clinical trials that will advance our knowledge about the underlying mechanisms of drug action, response, and safety in children at various developmental stages, and in women during pregnancy and lactation. Research topics include identifying small molecules and compounds or develop biologics for new targets for pharmacological intervention.

Assay Development and Screening to Discover Therapeutic or Imaging Agents for Diseases of Interest to the NIDDK (R01)
arrow PA-16-374

Posted Date: July 21, 2016
Expiration Date: September 8, 2019
Participating Organizations: NIDDK
R01 Research Project Grant: The goal of this Funding Opportunity Announcement (FOA) is to develop, validate, or conduct a screen using a novel assay to identify therapeutic or imaging agents relevant to health related outcomes of interest to the NIDDK. It is expected that state of the art measures of basic cellular processes or molecular events that are key mediators of disease pathogenesis are incorporated into these novel assays. Such assays should be useable in screens for molecules that modulate or monitor these processes or events in an unbiased and efficient manner. In particular, the NIDDK is interested in assays utilizing phenotypic readouts that provide opportunities to measure disease-relevant endpoints and lay the groundwork for future therapeutic and imaging agent discovery and development programs. It is expected that there is significant novelty in the assay approach to be developed or library to be screened and that this is articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, or performing later-stage optimization of therapeutic or imaging agents. At the end of the project period, a successful project will have either 1) developed and validated a novel assay suitable for identifying prototype therapeutic or imaging agents or 2) utilized a novel assay to identify prototype therapeutic or imaging agents.

Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01)
arrow PAR-16-330

Posted Date: June 15, 2016
Expiration Date: September 12, 2018
Participating Organizations: NINDS, NEI, NIAMSD, NIEHS, NIDA
U01 Research Project - Cooperative Agreements: The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests new research applications for Cooperative Agreement Research Projects (U01s) seeking support for research on the identification of small molecule or biologic lead compounds that are excellent candidates for therapeutic development. The scope of research supported by this FOA includes confirmation of molecular targets for therapeutic development, demonstration of in vitro activity of candidate therapeutics, preliminary in vivo proof-of-concept efficacy data, preliminary adsorption, distribution, metabolism, excretion, and toxicity (ADME/Tox) evaluations and pharmacokinetics/pharmacodynamics (PK/PD) data. These studies should result in the identification of at least one lead compound ready for optimization. Lead compounds are biologically active and synthetically feasible compounds where specificity, affinity, potency, target selectivity, efficacy, and safety have been established. Lead compounds should be ready for more advanced development under possible support from other programs such as the one described in the companion FOA "CounterACT Optimization of Therapeutic Lead Compound (U01)" (PAR-16-331).

Countermeasures Against Chemical Threats (CounterACT): Exploratory/Developmental (R21)
arrow PAR-15-315

Posted Date: Jan 30, 2015
Expiration Date: Jan 31, 2018
Participating Organizations: NINDS, NEI, NIAMSD, NIEHS, NIDA
R21 Research Project - Cooperative Agreements: Aimed to develop new and improved therapeutics to treat and/or prevent mortality and morbidity resulting from acute exposures to chemical agents identified by the U.S. Government (USG) as threats to the population. This R21 will be utilized to support 1-2 year pilot studies to generate tools and preliminary efficacy data for therapeutics to treat injuries resulting from exposure to these chemicals. Pilot studies may include the creation and validation of screening assays for therapy development, identification of candidate therapeutic targets and biological markers, and development of proof-of-principle efficacy data for the candidate therapy compounds. Supports the identification of candidate therapeutics using primary and secondary screening efforts to generate preliminary proof-of-principle in vitro and/or in vivo efficacy data of the "hits".

Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01)
arrow PAR-16-331

Posted Date: July 30, 2015
Expiration Date: Jan 31, 2018
Participating Organizations: NINDS, NEI, NIAMSD, NIEHS
U01 Research Project - Cooperative Agreements: The mission of the NIH Countermeasures Against Chemical Threats (CounterACT) program is to develop new and improved therapeutics to treat and/or prevent injuries resulting from exposure to chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents and toxic industrial chemicals and materials. This Funding Opportunity Announcement (FOA) requests research applications seeking support for research on the optimization of small molecule or biologic compounds that are excellent candidates for therapeutic development. A previously identified lead compound is required to be eligible for this funding opportunity. In this regard, lead compounds are defined as biologically active compounds or hits where affinity, potency, target selectivity, and preliminary safety have been established. The scope of research supported by this FOA includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans. It also includes bioanalytical assay development and validation, laboratory-scale and scale-up manufacturing of the product, and non-GLP toxicity and pharmacology studies.

Alzheimer's Drug-Development Program (U01)
arrow PAR-15-174

Posted Date: April 2, 2015
Expiration Date: May 8, 2018
Participating Organizations: NIA
U01 Research Project - Cooperative Agreements: The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies or, discovery activities such as high throughput screening and hit optimization.

Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01)
arrow PAR-16-266

Posted Date: May 17, 2016
Expiration Date: September 8, 2019
Participating Organizations: NIMH, NIA, NIAAA, NIDA, NIBIB
R01 Research Project - Cooperative Agreements: This Funding Opportunity Announcement (FOA) invites research grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies. Appropriate topic includes lead compound identification/development and syntheses of chemicals with suitable binding affinity, bio-distribution, pharmacokinetics, and physiochemical properties allowing radiochemical synthesis.

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3)
arrow PAR-17-205

Posted Date: March 9, 2017
Expiration Date: May 8, 2020
Participating Organizations: NINDS, NEI, NIA, NIAAA, DICHD, NIDCR, NIDA, NIMH, NCCIH
UG3/UH3 Research Project - Cooperative Agreements: The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Projects can initiate at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development.

If you have an assay you would like to screen that cannot be funded by one of the above opportunities, please e-mail us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or call us at either (561) 228-2150 or (561) 228-2101 to discuss other options available to you.

 

Leadid_Robot


Scripps Florida  |  130 Scripps Way, Jupiter, FL  33458  |  (561) 228-2000
The Scripps Research Institute  |  10550 North Torrey Pines Road, La Jolla, CA  92037  |  (858) 784-1000